Literature DB >> 11903747

High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis.

T Ishikawa1, T Ichida, S Yamagiwa, S Sugahara, K Uehara, S Okoshi, H Asakura.   

Abstract

BACKGROUND AND AIMS: The aims of the present study were to determine the occurrence rate of hepatocellular carcinoma (HCC) and to assess the risk factors for the development of HCC in compensated viral liver cirrhosis.
METHODS: Two hundred and thirty-nine cirrhotic patients (65 hepatitis B surface antigen (HBsAg) positive, 165 hepatitis C virus (HCV) antibody positive (anti-HCV), and nine with both HBsAg and anti-HCV positivity) were studied. The Kaplan-Meier method evaluated by a log-rank test was used to estimate the cumulative probability of HCC development. Independent predictors of HCC development were estimated by using the Cox proportional hazard regression analysis.
RESULTS: Dual infection manifested as HBsAg and anti-HCV positive was the highest risk of HCC. Multivariate analysis indicated that anti-HCV positive, HBsAg positive, and lactate dehydrogenase were independent predictors of the development of HCC among individuals with viral cirrhosis. In the HBsAg-positive group, a high-titer of HBV-DNA (more than 3.7 log genome equivalents (LGE)/mL) was most predictive of HCC development. In the anti-HCV-positive group, male gender and a high-titer of HCV-RNA (more than 1.0 Meq/mL) were predictive factors for the development of HCC.
CONCLUSIONS: Individuals with high viral loads should be monitored for the development of HCC. Clinical efforts at eradicating or reducing the viral load may reduce the risk for HCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11903747     DOI: 10.1046/j.1440-1746.2001.02616.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  17 in total

1.  Clinical features of hepatitis B virus-related hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

2.  Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Authors:  Chuan Chen; Dong-Ping Chen; Yan-Yan Gu; Liang-Hao Hu; Dan Wang; Jin-Huan Lin; Zhao-Shen Li; Jing Xu; Ge Wang
Journal:  Tumour Biol       Date:  2015-04-02

3.  Family history of liver cancer may modify the association between HBV infection and liver cancer in a Chinese population.

Authors:  Xing Liu; Aileen Baecker; Ming Wu; Jin-Yi Zhou; Jie Yang; Ren-Qiang Han; Pei-Hua Wang; Zi-Yi Jin; Ai-Min Liu; Xiaoping Gu; Xiao-Feng Zhang; Xu-Shan Wang; Ming Su; Xu Hu; Zheng Sun; Gang Li; Alan Fu; Su Yon Jung; Lina Mu; Na He; Liming Li; Jin-Kou Zhao; Zuo-Feng Zhang
Journal:  Liver Int       Date:  2019-07-10       Impact factor: 5.828

4.  Enhancement of hepatitis B virus replication by androgen and its receptor in mice.

Authors:  Yongjun Tian; Cheng-fu Kuo; Wen-ling Chen; Jing-hsiung James Ou
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

5.  Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.

Authors:  Toru Ishikawa
Journal:  World J Hepatol       Date:  2009-10-31

6.  Gastric cancer surgery for patients with liver cirrhosis.

Authors:  Yoshiyuki Ikeda; Tatsuo Kanda; Shin-Ichi Kosugi; Kazuhito Yajima; Atsushi Matsuki; Tsutomu Suzuki; Katsuyoshi Hatakeyama
Journal:  World J Gastrointest Surg       Date:  2009-11-30

7.  Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses coinfection in high HBV endemic area.

Authors:  Chun-Lei Fan; Lai Wei; Dong Jiang; Hong-Song Chen; Yan Gao; Ruo-Bing Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 8.  Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

Review 9.  Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

Review 10.  Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.